Randomised, double-blind, crossover study (n=14) comparing low (0.0143 mg/kg) and high (0.143 mg/kg) oral psilocybin versus placebo in adults with migraine.
Randomised, double-blind, crossover design in adults with migraine: each subject receives placebo and a psilocybin dose approximately 14 days apart with randomised order and assignment to low or high dose.
Participants maintain headache diaries to record frequency, intensity and associated symptoms; this preliminary study will inform design of larger trials.
Crossover comparing low and high dose oral psilocybin versus placebo; subjects receive placebo and psilocybin ~14 days apart in randomised order.
High dose psilocybin capsule (0.143 mg/kg).
Low dose psilocybin capsule (0.0143 mg/kg).
Microcrystalline cellulose capsule used as placebo in crossover sessions.
Microcrystalline cellulose capsule.